RE: FDA and the 505b2 pathway12 Jul 2025 18:17
You just know the prospects are looking good here when a mega de ramper shows up. It’s nearly always a new account and a first post here.
The lemmings article emphasises the risks which we are all aware of but ignores the exceptional positives like the NHS trial, a phase 3 for £800k, the phase 2b in the US and the other treatments in the pipeline.
How many biotechs have all that going for them with a measly mcap of £18m?
The article treats SVNS as if it was already a £500m company that is over valued. Risible!